← All indications
Sinusitis
Inflammation of the NASAL MUCOSA in one or more of the PARANASAL SINUSES.
Subtype terms (6)
More specific conditions that are subtypes of Sinusitis in the MeSH hierarchy.
- Allergic Fungal Sinusitis
1 drug approved
- Ethmoid Sinusitis
- Frontal Sinusitis
- Maxillary Sinusitis
10 drugs approved
- Rhinosinusitis
- Sphenoid Sinusitis
Drugs by status
Approved for this indication (17)
Phase 4 trials (39)
- levofloxacin
- montelukast
- propofol
- methylprednisolone
- almotriptan
- urea
- procaine benzylpenicillin
- cefdinir
- cefditoren
- mometasone
- oxycodone
- doxycycline
- prednisone
- ibuprofen
- dupilumab
- sevoflurane
- escitalopram
- omalizumab
- mepolizumab
- mupirocin
- acetaminophen
- saccharomyces boulardii
- epinephrine
- celecoxib
- dexmedetomidine
- gentamicin
- triamcinolone
- budesonide
- tranexamic acid
- prednisolone
- +9 more
Phase 3 trials (32)
- vitamin d3
- fluticasone
- acetylcysteine
- benralizumab
- tobramycin
- bno 1016
- pranlukast
- gentian root
- dornase alfa
- primrose oil
- beclomethasone
- mitomycin
- lebrikizumab
- luffa operculate
- serum
- rimegepant
- lidocaine
- regn3500
- reslizumab
- itraconazole
- xylitol
- amphotericin b
- common sorrel
- european vervain
- elder flower
- cefpodoxime
- onabotulinumtoxinA
- tezepelumab
- rafamin
- shr-1905
- +2 more
Phase 2 trials (26)
- roflumilast
- simvastatin
- colloidal silver
- theophylline
- brensocatib
- esmolol
- betamethasone
- fevipiprant
- esketamine
- labetalol
- nitric oxide
- magnesium sulfate
- bupivacaine
- vancomycin
- verapamil
- dexpramipexole
- methoxyflurane
- quinine
- etokimab
- allogenic mesenchymal stem cell derived from olfactory mucosa
- cbp-201
- cm326
- sar443765
- tqh2722
- upb-101
- cm512
Phase 1 trials (5)
Other trials (33)
- leptospermum honey
- human fibrin
- bee venom
- bifidobacterium animalis
- epoetin
- cetirizine
- chitosan
- gabapentin
- isoflurane
- glycopyrronium
- zanamivir
- albumin (Human)
- iohexol
- nigella sativa
- platelet rich fibrin
- ceftriaxone
- acetylsalicylic acid
- sufentanil
- cyclamen europaeum
- bacillus subtilis
- neostigmine
- eukalyptol
- pregabalin
- phenylpropanolamine
- cephalexin
- sugammadex
- flurbiprofen
- neomycin
- erythromycin
- dexamethasone
- +3 more
Organizations
Organization Involved with Phase 4 Indications (54)
- Abbott
- Forest Laboratories
- Genentech
- Sanofi
- Novartis
- CPL Associates
- Clinvest
- Galsor S.r.l.
- Korea United Pharm. Inc.
- National Institutes of Health (NIH)
- National Heart, Lung, and Blood Institute (NHLBI)
- National Institute of Allergy and Infectious Diseases (NIAID)
- Albany Medical College
- Algemeen Ziekenhuis Maria Middelares
- Harvard University
- Gazi University
- University of Washington
- Johns Hopkins University
- Loma Linda University
- Mahidol University
- McGill University
- Medical University of Lodz
- Northwestern University
- Ondokuz Mayıs University
- Stanford University
- Thammasat University
- Tufts University
- University of Michigan
- University of Oslo
- University of Oulu
- +24 more
Organization Involved with Phase 3 Indications (43)
- CSL Behring
- Accentia Biopharmaceuticals
- Regeneron
- Roche
- Sandoz
- Merck
- Chiesi
- GlaxoSmithKline
- Intersect ENT
- NeuTec Pharma
- OptiNose AS
- Pari Pharma GmbH
- Bionorica
- Zurita Laboratorio Farmaceutico Ltda.
- University of Jena
- University of Pittsburgh
- Benha University
- Centre Hospitalier Intercommunal Creteil
- Eastern Virginia Medical School
- Emory University
- Kaiser Permanente
- LifeBridge Health
- Norwegian University of Science and Technology
- Ochsner Health System
- Shanxi Medical University
- University of Florida
- University of Rochester
- University of Toronto
- Capital Medical University
- University of Chile
- +13 more
Organization Involved with Phase 2 Indications (17)
- AnaptysBio, Inc.
- Glaxo Wellcome
- Kyowa Hakko Kirin
- Knopp Biosciences
- Naryx Pharma
- University of Pennsylvania
- University of South Florida
- GeneOne Life Science
- Schulich School of Medicine and Dentistry
- University of Texas, Galveston
- KhonKaen University
- Department of Veteran Affairs
- University of Western Ontario
- Adams Laboratories
- Gossamer Bio Inc.
- Lyra Therapeutics
- Sanotize Research and Development Corp.
Organization Involved with Phase 1 Indications (9)
Organization Involved with Other Experimental Indications (21)
- Mallinckrodt
- STS Medical
- Dey
- Immune Enhancement Project
- Huazhong University of Science and Technology
- Siriraj Hospital
- University of Iowa
- University of Kansas
- University of South Carolina
- University of Tampere
- University of Alberta
- Yale University
- University of Virginia
- Assiut University
- Tel Aviv University
- Medical University of South Carolina
- University of Haifa
- Memorial Clinical Reasearch, OK
- National Natural Science Foundation of China
- Thrasher Research Fund
- Nanyang Technological University